❓ Can we measure #bloodpressure in the arm with a closed AV #fistula after kidney transplant?

✅ YES! Here is our our latest study published in Hypertension @ahajournals.bsky.social showing no significant BP difference between arms post-AVF closure

👉🏼 www.ahajournals.org/doi/10.1161/...

This is what we were waiting for. A direct comparison between apixaban and rivaroxaban for the treatment of acute VTE. Apixaban reduces bleeding risk in the first 3 months by >50%!

Practice changing investigator-initiated RCT.

#ISTH2025

Lepodisiran, an extended-duration, small interfering RNA, reduced lipoprotein(a) concentrations in participants with elevated levels. Full ALPACA trial results and Research Summary: nej.md/4kWjJyn

#MedSky #CardioSky

Cancer associated DVT results in several clinical outcomes - but can we predict which ones? 🤔

Findings from the ONCO-DVT Study: Patients with symptomatic DVT had higher risk of recurrent VTE than patients who had asymptomatic DVT.

Check out the data here: www.rpthjournal.org/article/S247...

An important message from dr. Lundström 📢 don't forget the AVF after transplantation 📢. With suggestions when to Ligate⬇️ #VAS2025

Last day at #VAS2025 and it starts with no other than Dr Claudio Ronco. Really interesting talk about the history of hemodialysis and vascular access

Welcome to the #VAS2025 congress! This year, the young committee will also be present at these sessions. Come and join in!

Extended anticoagulant therapy with reduced-dose apixaban was noninferior to full-dose in patients with active cancer and #cvVTE, based on findings from the API-CAT trial presented at #ACC25.

Read the journal scan to learn more: bit.ly/43w2A8v

#CardioSky #MedSky

#SOUL trial presented at #ACC25. Oral #semaglutide reduced 3-pt major adverse cardiovascular events by 14% in patients with T2D, even with high background SGLTi use. In exploratory analysis, oral sema also reduced major limb events. #CardioSky @accintouch.bsky.social

Article of the month📣 Interesting retrospective cohort study from Japan🤔! Showing that femoro-femoral arteriovenous fistulas can be a viable and durable option when traditional access points are no longer feasible!

jvascsurg.org/article/S0741-…

This JAMA Insights explores effective communication strategies for clinicians who do not specialize in treating obesity in how to introduce conversations about weight loss with their patients and offer them support and treatment. https://ja.ma/426a9RU

Regulatory agencies have issued warnings about JAK inhibitors and VTE risk—but what does the evidence actually say?

Our latest review breaks down the data, limitations, and next steps.
@davidmsmadja.bsky.social @isabellemahe.bsky.social

📑 Read now: buff.ly/4ijJQNq